With the market going down rather predictably each day, we at GuruFocus have decided that 52-Week Low is good, but 52-Week High is better. The market is too depressing; we all need some fresh air. We are going to publish a new column called “Stocks At 52-week Highs”, for now, until the market return to normalcy and such a column is no longer necessary.
According to GuruFocus updates, these stocks have reached their 52-Week Highs recently.
O'Reilly Automotive Inc. (ORLY, Financial) Reached the 52-Week High of $32.84
O'Reilly Automotive Inc. is a specialty retailer and supplier of automotive aftermarket parts, tools, supplies, equipment and accessories to both ``do-it-yourself`` customers and professional mechanics. Naturally, when people do not buy new cars, they do not quit driving -- they just drive older cars, fixed, of course.
O'Reilly Automotive Inc. has a market cap of $4.4 billion; its shares were traded at around $32.23 with a P/E ratio of 19.1 and P/S ratio of 1.23. O'Reilly Automotive Inc. had an annual average earning growth of 19% over the past 10 years. GuruFocus rated O'Reilly Automotive Inc. the business predictability rank of 4.5-star.
The company recently reported fourth quarter and 2008 annual financials:
Sales for the fourth quarter ended December 31, 2008, totaled $1.1 billion, up 84% from $604 million for the same period a year ago. For the year ended December 31, 2008, sales increased $1.05 billion, or 42%, to $3.58 billion from $2.52 billion for the year ended December 31, 2007.
Net income for the year ended December 31, 2008, totaled $186.2 million, down 4.0% from $194.0 million for the year ended December 31, 2007. Diluted earnings per common share for the year ended December 31, 2008, decreased 11.4% to $1.48 on 125.4 million shares versus $1.67 a year ago on 116.1 million shares.
The Company’s fourth quarter and full year results include charges related to the July 11, 2008, acquisition of CSK Automotive, Inc (“CSK”).
ORLY is in the portfolios of Chuck Akre of Akre Capital Management, LLC, Ruane Cunniff of Ruane & Cunniff & Goldfarb Inc, PRIMECAP Management, Jean-Marie Eveillard of Arnhold & S. Bleichroeder Advisers, LLC.
Insiders have been selling: Sell: SVP of Distribution Gregory D Johnson sold 5,000 shares of ORLY stock on 02/26/2009 at the average price of $33.43; the price of the stock has decreased by 3.59% since. Sell: SVP of Merchandise Michael D Swearengin sold 2,800 shares of ORLY stock on 02/24/2009 at the average price of $33; the price of the stock has decreased by 2.33% since. Sell: SVP of Store Operations/Sales Jeff M Shaw sold 8,900 shares of ORLY stock on 02/24/2009 at the average price of $33.25; the price of the stock has decreased by 3.07% since. Sell: Director Paul R Lederer sold 10,000 shares of ORLY stock on 02/24/2009 at the average price of $32.51; the price of the stock has decreased by 0.86% since. In other words, insiders are selling collectively.
Career Education Corp. (CECO, Financial) Reached the 52-Week High of $23.81
Career Education Corporation is a provider of private for-profit post-secondary education with campuses throughout the United States and Canada, the United Kingdom, and the United Arab Emirates. Their schools offer a variety of master's degree, bachelor's degree, associate degree, and diploma programs in career-oriented disciplines. They offer educational programs principally in the following four career-related fields of study: Visual Communication and Design Technologies, Information Technology, Business Studies, and Culinary Arts. Career Education Corp. has a market cap of $2.12 billion; its shares were traded at around $23.81 with a P/E ratio of 25.9 and P/S ratio of 1.27.
When people get laid off, they go to school and learn a new skill for a new career. With the nation’s unemployment rate reached 7.6% and climbing, no wonder CECO’s business is doing very well these days.
The company recently reported fourth quarter 2008 consolidated revenue from continuing operations of $431.8 million and consolidated income from continuing operations of $34.3 million, or $0.38 per diluted share. For the full year of 2008, consolidated revenue from continuing operations was $1.705 billion and consolidated income from continuing operations was $69.6 million, or $0.77 per diluted share.
Sell: VP Academic Affairs Donna L Gray sold 284 shares of CECO stock on 12/03/2008 at the average price of $17; the price of the stock has increased by 40.06% since.
CV Therapeutics Inc. (CVTX, Financial) Reached the 52-Week High of $15.43
CV Therapeutics is a biopharmaceutical company engaged in the discovery and development of new small molecule drugs to treat cardiovascular disease, the leading cause of death in the United States. The company has several research and preclinical development programs designed to bring additional drug candidates into human clinical testing. In addition to its approved products, ranolazine (Ranexa) and regadenoson (Lexiscan), the company is conducting clinical trials for a number of additional drug candidates for conditions, including atrial fibrillation, heart failure and diabetes, among others.
In other words, the company is in business of finding the wonder drug. It doesn’t matter what the economy does as long as the prospect of their drug is good.
CV Therapeutics Inc. has a market cap of $951.8 million; its shares were traded at around $15.43 with and P/S ratio of 11.49. CV Therapeutics Inc. had an annual average earning growth of 7.8% over the past 5 years.
The company recently reported its fourth quarter and annual results: For the quarter ended December 31, 2008, the company recorded $31.5 million of net product sales of Ranexa(R) (ranolazine extended-release tablets) in the U.S., which represents an increase of four percent compared to the $30.3 million of net product sales recorded in the prior quarter ended September 30, 2008 and an increase of 51 percent compared to the $20.9 million of net product sales recorded in the same quarter in the prior year. For the full year ended December 31, 2008, the company recorded $109.3 million of net product sales of Ranexa in the U.S., which represents an increase of 64 percent compared to the $66.7 million of net product sales recorded in the prior full year ended December 31, 2007.
For the year ended December 31, 2008, the company reported a net loss of $98.5 million, or $1.61 per share, compared to a net loss of $181.0 million, or $3.05 per share, for the year ended December 31, 2007
"2008 was an exceptional year for CV Therapeutics and its shareholders, as we received three major regulatory approvals, retired more than $100 million in debt, completed two major strategic transactions bringing in more than $250 million in non-dilutive net cash, grew our Ranexa business by 64 percent year-over-year, and saw our share price outperform the NASDAQ by more than 40 percent," said Dr. Louis Lange, chairman and chief executive officer of CV Therapeutics.
"With the company's solid cash position, the full promotional launch of the improved U.S. Ranexa labeling and the imminent introduction of Ranexa in Europe, we expect 2009 to be another outstanding year, highlighted by increasing revenues and pipeline advancement with CVT-3619 and other programs. We expect to be able to provide an update regarding profitability timing by the middle of the year," Lange added.
Insider are selling recently: Sell: SVP, Drug Discovery & Dev Brent K Blackburn sold 1,500 shares of CVTX stock on 02/06/2009 at the average price of $15.5; the price of the stock has decreased by 0.45% since. Sell: SVP, Drug Discovery & Dev Brent K Blackburn sold 1,500 more shares of CVTX stock on 01/07/2009 at the average price of $9.38; the price of the stock has increased by 64.5% since. Sell: SVP COMMERCIAL OPERATIONS Lewis J Stuart sold 3,002 shares of CVTX stock on 12/10/2008 at the average price of $8.54; the price of the stock has increased by 80.68% since.
Interwoven Inc. (IWOV, Financial) Reached the 52-Week High of $16.07
Interwoven Inc. is a provider of software products and services that help businesses and other organizations manage the information that makes up the content of their web sites. The company has designed the software products to help companies rapidly and efficiently develop maintain and extend large web sites that are essential to their businesses. The principal product TeamSite incorporates widely accepted Internet industry standards and is designed with an open architecture that allows it to support a wide variety of Internet software products. Interwoven Inc. has a market cap of $739.41 million; its shares were traded at around $16.07 with a P/E ratio of 21.7 and P/S ratio of 2.84.
The company recently reported fourth quarter and annual results: total revenues of $69.8 million for the fourth quarter of 2008, an increase of 11% from total revenues of $62.9 million for the fourth quarter of 2007. Net income for the fourth quarter of 2008 was $10.7 million, or $0.23 per share, compared to net income of $10.7 million, or $0.23 per share, for the same period in 2007.
For the year ended December 31, 2008, Interwoven reported total revenues of $260.3 million, an increase of 15% from total revenues of $225.7 million for 2007. Net income for the year ended December 31, 2008, calculated in accordance with generally accepted accounting principles, was $32.0 million, or $0.69 per share, compared to a net income of $23.7 million, or $0.51 per share, for 2007.
Applied Signal Technology Inc. (APSG, Financial) Reached the 52-Week High of $19.59
Applied Signal Technology Inc. designs, develops and manufactures signal processing equipment to collect and process a wide range of telecommunication signals. This equipment is used for reconnaissance of foreign telecommunications predominantly by the United States Government and allied foreign governments for certain industrial applications and for defense communications systems. Signal reconnaissance systems are composed of collection equipment and processing equipment.
Applied Signal Technology Inc. has a market cap of $229.77 million; its shares were traded at around $19.59 with a P/E ratio of 29.1 and P/S ratio of 1.23. The dividend yield of Applied Signal Technology Inc. stocks is 2.79%.
Applied Signal Technology recently announced operating results for the first quarter fiscal year 2009, ended January 30, 2009. Revenues for the first quarter increased 6.2% to $45.4 million versus $42.7 million in the year-ago period. Net income for the first quarter of fiscal 2009 grew by 133% to $3.5 million versus $1.5 million in the year-ago period. Earnings per diluted share for the period were $0.27 as compared to $0.12 in the same period of the prior year, an increase of 125%.
Oceanaut Inc (OKN, Financial) Reached the 52-Week High of $8.19
The prices of Oceanaut Inc (OKN) shares have reached the 52-Week High of $8.19 recently. Oceanaut Inc. is a blank check company formed for the purpose of acquiring through a merger capital stock exchange, asset acquisition, stock purchase, or other similar business combination vessels of one or more operating businesses in the shipping industry.
On Feb 18, 2009, the company announced that its board of directors had determined that the Company will not consummate a business combination by the March 6, 2009 deadline provided for in its charter, and that it is advisable that the Company be dissolved. As a result, Oceanaut intends to convene a special meeting of its shareholders on March 16, 2009 to vote on a plan of liquidation and dissolution of the Company. The record date for the special meeting is February 27, 2009. The Company intends to begin promptly the process of dissolution and liquidating its trust account in accordance with its charter and applicable Marshall Islands law. Assuming shareholder approval of the Company’s plan of liquidation, the Company expects to liquidate its trust account and make an estimate payment of approximately $ 8.27 per share of common stock.
Zion Oil & Gas Inc (ZN, Financial) Reached the 52-Week High of $13.45
Zion Oil & Gas Inc. was founded for the purpose of exploring for oil and gas in Israel and reaching production levels that would help Israel become an energy independent country. Zion Oil & Gas a Delaware corporation explores for oil and gas in Israel in areas located on-shore between Haifa and Tel Aviv. It currently holds two petroleum exploration licenses the Joseph and the Asher-Menashe Licenses between Netanya on the south and Haifa on the north. From its inception the calling of Zion Oil & Gas has been to assist Israel in the restoration of the Land by finding and producing oil and gas helping to make Israel politically and economically independent. Zion Oil & Gas Inc has a market cap of $130.95 million; its shares were traded at around $13.45.
Again, Go here for the complete list of 52-Week Highs.
According to GuruFocus updates, these stocks have reached their 52-Week Highs recently.
O'Reilly Automotive Inc. (ORLY, Financial) Reached the 52-Week High of $32.84
O'Reilly Automotive Inc. is a specialty retailer and supplier of automotive aftermarket parts, tools, supplies, equipment and accessories to both ``do-it-yourself`` customers and professional mechanics. Naturally, when people do not buy new cars, they do not quit driving -- they just drive older cars, fixed, of course.
O'Reilly Automotive Inc. has a market cap of $4.4 billion; its shares were traded at around $32.23 with a P/E ratio of 19.1 and P/S ratio of 1.23. O'Reilly Automotive Inc. had an annual average earning growth of 19% over the past 10 years. GuruFocus rated O'Reilly Automotive Inc. the business predictability rank of 4.5-star.
The company recently reported fourth quarter and 2008 annual financials:
Sales for the fourth quarter ended December 31, 2008, totaled $1.1 billion, up 84% from $604 million for the same period a year ago. For the year ended December 31, 2008, sales increased $1.05 billion, or 42%, to $3.58 billion from $2.52 billion for the year ended December 31, 2007.
Net income for the year ended December 31, 2008, totaled $186.2 million, down 4.0% from $194.0 million for the year ended December 31, 2007. Diluted earnings per common share for the year ended December 31, 2008, decreased 11.4% to $1.48 on 125.4 million shares versus $1.67 a year ago on 116.1 million shares.
The Company’s fourth quarter and full year results include charges related to the July 11, 2008, acquisition of CSK Automotive, Inc (“CSK”).
ORLY is in the portfolios of Chuck Akre of Akre Capital Management, LLC, Ruane Cunniff of Ruane & Cunniff & Goldfarb Inc, PRIMECAP Management, Jean-Marie Eveillard of Arnhold & S. Bleichroeder Advisers, LLC.
Insiders have been selling: Sell: SVP of Distribution Gregory D Johnson sold 5,000 shares of ORLY stock on 02/26/2009 at the average price of $33.43; the price of the stock has decreased by 3.59% since. Sell: SVP of Merchandise Michael D Swearengin sold 2,800 shares of ORLY stock on 02/24/2009 at the average price of $33; the price of the stock has decreased by 2.33% since. Sell: SVP of Store Operations/Sales Jeff M Shaw sold 8,900 shares of ORLY stock on 02/24/2009 at the average price of $33.25; the price of the stock has decreased by 3.07% since. Sell: Director Paul R Lederer sold 10,000 shares of ORLY stock on 02/24/2009 at the average price of $32.51; the price of the stock has decreased by 0.86% since. In other words, insiders are selling collectively.
Career Education Corp. (CECO, Financial) Reached the 52-Week High of $23.81
Career Education Corporation is a provider of private for-profit post-secondary education with campuses throughout the United States and Canada, the United Kingdom, and the United Arab Emirates. Their schools offer a variety of master's degree, bachelor's degree, associate degree, and diploma programs in career-oriented disciplines. They offer educational programs principally in the following four career-related fields of study: Visual Communication and Design Technologies, Information Technology, Business Studies, and Culinary Arts. Career Education Corp. has a market cap of $2.12 billion; its shares were traded at around $23.81 with a P/E ratio of 25.9 and P/S ratio of 1.27.
When people get laid off, they go to school and learn a new skill for a new career. With the nation’s unemployment rate reached 7.6% and climbing, no wonder CECO’s business is doing very well these days.
The company recently reported fourth quarter 2008 consolidated revenue from continuing operations of $431.8 million and consolidated income from continuing operations of $34.3 million, or $0.38 per diluted share. For the full year of 2008, consolidated revenue from continuing operations was $1.705 billion and consolidated income from continuing operations was $69.6 million, or $0.77 per diluted share.
Sell: VP Academic Affairs Donna L Gray sold 284 shares of CECO stock on 12/03/2008 at the average price of $17; the price of the stock has increased by 40.06% since.
CV Therapeutics Inc. (CVTX, Financial) Reached the 52-Week High of $15.43
CV Therapeutics is a biopharmaceutical company engaged in the discovery and development of new small molecule drugs to treat cardiovascular disease, the leading cause of death in the United States. The company has several research and preclinical development programs designed to bring additional drug candidates into human clinical testing. In addition to its approved products, ranolazine (Ranexa) and regadenoson (Lexiscan), the company is conducting clinical trials for a number of additional drug candidates for conditions, including atrial fibrillation, heart failure and diabetes, among others.
In other words, the company is in business of finding the wonder drug. It doesn’t matter what the economy does as long as the prospect of their drug is good.
CV Therapeutics Inc. has a market cap of $951.8 million; its shares were traded at around $15.43 with and P/S ratio of 11.49. CV Therapeutics Inc. had an annual average earning growth of 7.8% over the past 5 years.
The company recently reported its fourth quarter and annual results: For the quarter ended December 31, 2008, the company recorded $31.5 million of net product sales of Ranexa(R) (ranolazine extended-release tablets) in the U.S., which represents an increase of four percent compared to the $30.3 million of net product sales recorded in the prior quarter ended September 30, 2008 and an increase of 51 percent compared to the $20.9 million of net product sales recorded in the same quarter in the prior year. For the full year ended December 31, 2008, the company recorded $109.3 million of net product sales of Ranexa in the U.S., which represents an increase of 64 percent compared to the $66.7 million of net product sales recorded in the prior full year ended December 31, 2007.
For the year ended December 31, 2008, the company reported a net loss of $98.5 million, or $1.61 per share, compared to a net loss of $181.0 million, or $3.05 per share, for the year ended December 31, 2007
"2008 was an exceptional year for CV Therapeutics and its shareholders, as we received three major regulatory approvals, retired more than $100 million in debt, completed two major strategic transactions bringing in more than $250 million in non-dilutive net cash, grew our Ranexa business by 64 percent year-over-year, and saw our share price outperform the NASDAQ by more than 40 percent," said Dr. Louis Lange, chairman and chief executive officer of CV Therapeutics.
"With the company's solid cash position, the full promotional launch of the improved U.S. Ranexa labeling and the imminent introduction of Ranexa in Europe, we expect 2009 to be another outstanding year, highlighted by increasing revenues and pipeline advancement with CVT-3619 and other programs. We expect to be able to provide an update regarding profitability timing by the middle of the year," Lange added.
Insider are selling recently: Sell: SVP, Drug Discovery & Dev Brent K Blackburn sold 1,500 shares of CVTX stock on 02/06/2009 at the average price of $15.5; the price of the stock has decreased by 0.45% since. Sell: SVP, Drug Discovery & Dev Brent K Blackburn sold 1,500 more shares of CVTX stock on 01/07/2009 at the average price of $9.38; the price of the stock has increased by 64.5% since. Sell: SVP COMMERCIAL OPERATIONS Lewis J Stuart sold 3,002 shares of CVTX stock on 12/10/2008 at the average price of $8.54; the price of the stock has increased by 80.68% since.
Interwoven Inc. (IWOV, Financial) Reached the 52-Week High of $16.07
Interwoven Inc. is a provider of software products and services that help businesses and other organizations manage the information that makes up the content of their web sites. The company has designed the software products to help companies rapidly and efficiently develop maintain and extend large web sites that are essential to their businesses. The principal product TeamSite incorporates widely accepted Internet industry standards and is designed with an open architecture that allows it to support a wide variety of Internet software products. Interwoven Inc. has a market cap of $739.41 million; its shares were traded at around $16.07 with a P/E ratio of 21.7 and P/S ratio of 2.84.
The company recently reported fourth quarter and annual results: total revenues of $69.8 million for the fourth quarter of 2008, an increase of 11% from total revenues of $62.9 million for the fourth quarter of 2007. Net income for the fourth quarter of 2008 was $10.7 million, or $0.23 per share, compared to net income of $10.7 million, or $0.23 per share, for the same period in 2007.
For the year ended December 31, 2008, Interwoven reported total revenues of $260.3 million, an increase of 15% from total revenues of $225.7 million for 2007. Net income for the year ended December 31, 2008, calculated in accordance with generally accepted accounting principles, was $32.0 million, or $0.69 per share, compared to a net income of $23.7 million, or $0.51 per share, for 2007.
Applied Signal Technology Inc. (APSG, Financial) Reached the 52-Week High of $19.59
Applied Signal Technology Inc. designs, develops and manufactures signal processing equipment to collect and process a wide range of telecommunication signals. This equipment is used for reconnaissance of foreign telecommunications predominantly by the United States Government and allied foreign governments for certain industrial applications and for defense communications systems. Signal reconnaissance systems are composed of collection equipment and processing equipment.
Applied Signal Technology Inc. has a market cap of $229.77 million; its shares were traded at around $19.59 with a P/E ratio of 29.1 and P/S ratio of 1.23. The dividend yield of Applied Signal Technology Inc. stocks is 2.79%.
Applied Signal Technology recently announced operating results for the first quarter fiscal year 2009, ended January 30, 2009. Revenues for the first quarter increased 6.2% to $45.4 million versus $42.7 million in the year-ago period. Net income for the first quarter of fiscal 2009 grew by 133% to $3.5 million versus $1.5 million in the year-ago period. Earnings per diluted share for the period were $0.27 as compared to $0.12 in the same period of the prior year, an increase of 125%.
Oceanaut Inc (OKN, Financial) Reached the 52-Week High of $8.19
The prices of Oceanaut Inc (OKN) shares have reached the 52-Week High of $8.19 recently. Oceanaut Inc. is a blank check company formed for the purpose of acquiring through a merger capital stock exchange, asset acquisition, stock purchase, or other similar business combination vessels of one or more operating businesses in the shipping industry.
On Feb 18, 2009, the company announced that its board of directors had determined that the Company will not consummate a business combination by the March 6, 2009 deadline provided for in its charter, and that it is advisable that the Company be dissolved. As a result, Oceanaut intends to convene a special meeting of its shareholders on March 16, 2009 to vote on a plan of liquidation and dissolution of the Company. The record date for the special meeting is February 27, 2009. The Company intends to begin promptly the process of dissolution and liquidating its trust account in accordance with its charter and applicable Marshall Islands law. Assuming shareholder approval of the Company’s plan of liquidation, the Company expects to liquidate its trust account and make an estimate payment of approximately $ 8.27 per share of common stock.
Zion Oil & Gas Inc (ZN, Financial) Reached the 52-Week High of $13.45
Zion Oil & Gas Inc. was founded for the purpose of exploring for oil and gas in Israel and reaching production levels that would help Israel become an energy independent country. Zion Oil & Gas a Delaware corporation explores for oil and gas in Israel in areas located on-shore between Haifa and Tel Aviv. It currently holds two petroleum exploration licenses the Joseph and the Asher-Menashe Licenses between Netanya on the south and Haifa on the north. From its inception the calling of Zion Oil & Gas has been to assist Israel in the restoration of the Land by finding and producing oil and gas helping to make Israel politically and economically independent. Zion Oil & Gas Inc has a market cap of $130.95 million; its shares were traded at around $13.45.
Again, Go here for the complete list of 52-Week Highs.
